XML 42 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Loss Per Common Share
 9 Months Ended 12 Months Ended
Sep. 30, 2017
Dec. 31, 2016
Earnings Per Share [Abstract]    
Loss Per Common Share
Loss Per Common Share
Basic loss per common share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive options and warrants to purchase common stock that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the three and nine months ended September 30, 2017 and 2016.
The following is the computation of loss per common share for the three and nine months ended September 30, 2017 and 2016:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2017
 
2016
 
2017
 
2016
Net loss
$
(2,313
)
 
$
(3,526
)
 
$
(8,937
)
 
$
(11,299
)
Weighted-average basic and diluted common shares outstanding
1,725,906

 
97,691

 
183,395

 
109,539

Loss per share - basic and diluted
$
(1.34
)
 
$
(36.09
)
 
$
(48.73
)
 
$
(103.15
)

The outstanding securities presented below were excluded from the calculation of net loss per common share, because such securities would have been anti-dilutive due to the Company’s net loss per share during the periods ending on the dates presented:
 
September 30,
 
2017
 
2016
Options to purchase common stock
3,678,359

 
3,038,772

Warrants to purchase common stock
163,174

 
—
Loss Per Common Share
Basic loss per common share is calculated by dividing net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc. by the weighted-average number of shares of common stock outstanding during the period. The number of shares outstanding has been adjusted to reflect the corporate conversion completed on July 9, 2015 as if it had occurred as of the beginning of the respective periods presented. Diluted loss per common share is calculated using the treasury share method by giving effect to all potentially dilutive securities that were outstanding. Potentially dilutive common stock options that were outstanding during the periods presented were excluded from the diluted loss per share calculation because such shares had an anti-dilutive effect due to the net loss reported in those periods. Therefore, basic and diluted loss per common share is the same for each of the years ended December 31, 2016 and 2015.
The following is the computation of loss per common share for the years ended December 31, 2016 and 2015:
 
Years Ended
December 31,
 
2016
 
2015
Net loss attributable to members of AuraSense Therapeutics, LLC/stockholders of Exicure, Inc.
$
(16,941
)
 
$
(13,151
)
Weighted-average basic and diluted common shares outstanding
228,447

 
108,123

Loss per share - basic and diluted
$
(74.16
)
 
$
(121.63
)
Potentially dilutive shares excluded from computation of weighted-average diluted common shares outstanding
6,222,448

 
6,528,052